The short answer
An exact interaction between Crataegus monogyna and labetalol has not been established. Review the species, plant part and extract before adding hawthorn to heart treatment.
What this answer covers
Oral labetalol with the exact supplement preparation described below.
- Supplement or preparation
- Crataegus monogyna
- Medication ingredient
- labetalol
The largest trial gives useful context
A large heart-failure study tested one standardized hawthorn leaf-and-flower extract alongside usual treatment, which often included beta blockers. Overall adverse events were similar to placebo. That is reassuring context, not proof for this exact medicine and every hawthorn product.
A blood-pressure claim needs closer evidence
A small hypertension pilot did not find significant differences in its overall treatment comparisons. Its exploratory trend does not establish that C. monogyna causes added low blood pressure with labetalol.
Match the species and plant part
Medicinal leaf-and-flower guidance includes C. monogyna and related species. It does not validate every fruit, root or mixed extract. The monograph’s lack of reported interactions is not a guarantee of safety, and no special interval for this pair was established.
Keep the prescribed treatment plan
Do not stop labetalol abruptly or adjust the dose to compensate for a supplement. Bring the product label and your recent blood-pressure and pulse readings to your pharmacist or prescriber so any change can be assessed in context.
Evidence and practical considerations
Side effects & toxicity
An exact interaction between Crataegus monogyna and labetalol has not been established. Review the species, plant part and extract before adding hawthorn to heart treatment.
- Exact scope
- Oral labetalol with the exact supplement preparation described below. with Oral labetalol; intravenous cases are identified as indirect route evidence where discussed.
- Medication form and route
- oral
What remains uncertain
- Heart-failure co-treatment trial did not show overall added adverse events; pilot pressure comparison was nonsignificant. Neither establishes exact C.monogyna/labetalol hypotension, absorption loss, nutrient need or timing.
Factors that may matter: Exact ingredient and preparation; Kidney function and clinical indication; Concomitant medicines.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral labetalol.
Oral labetalol undergoes extensive first-pass metabolism, mainly glucuronide conjugation. Food increases bioavailability. This is separate from intravenous exposure and emergency treatment.
How this applies: Exact active-ingredient and oral-route context.
Label omission of an herb does not prove safety. No invented exact supplement interaction rate or universal spacing rule.
Source 2: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 2,681 adults with chronic heart failure in a randomized trial.
Overall adverse events were similar and the primary cardiac-event endpoint did not significantly differ.
How this applies: Provides relevant contrary co-treatment evidence without transferring an exact pair estimate.
Not a dedicated trial of each beta blocker with pure Crataegus monogyna. One standardized extract cannot establish safety of all species, parts or products.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Thirty-six mildly hypertensive participants.
Overall treatment comparisons did not show significant blood-pressure differences; a hawthorn diastolic trend was exploratory.
How this applies: Does not prove additive hypotension with a named medicine.
Small pilot; not an exact beta-blocker interaction and species/product limits apply.
Source 4: Regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: People considering covered hawthorn leaf-and-flower preparations.
The final monograph lists no reported interactions and requires medical assessment of cardiac symptoms.
How this applies: Supports exact material review and excludes claims of a confirmed universal interaction.
No reports is not proof of safety. Revision1 was still identified as a draft on the inspected EMA listing.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft with exact preparation limits, contrary findings and source-access details. Clinical review not recorded. | |
| Research summary published |
Article revision: fb0615190665f227
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.